ClinicalTrials.gg
CompletedNCT04889157Updated Oct 1, 2024Results posted

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

A Phase 1 interventional study of PF-06882961 and Placebo in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.

Enrollment
62nd of 79
20 · median 50
Started
2021
with 2 others
Phase 1
47 of 80
none open now
Registered
73rd of 80
by date

Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 62nd largest by enrollment of the 79 interventional ones that give a count, is one of 3 that started in 2021, is one of 47 in phase 1, and was the 73rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Diabetes Mellitus, Type 2 by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with T2DM who are taking metformin monotherapy as their only antihyperglycemic treatment
  • greater than or equal to 7% and less than or equal to 10.5%
  • Total body weight >50 kg (110 lb) with of 22.5 to 45.4 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Diagnosis of Type 1 diabetes mellitus or secondary forms of diabetes
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or within 6 months of Screening
  • Any not considered cured
  • Personal or family history of MTC or MEN2, or participants with suspected MTC
  • Acute pancreatitis or history of chronic pancreatitis
  • Acute gallbladder disease
  • Known history of , , or syphilis, or positive testing of them
  • Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
  • abnormalities
  • Positive urine drug test
  • Clinical relevant laboratory tests abnormalities
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PF-06882961

    Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg

    Drug: PF-06882961

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)

  • DrugPlacebo

    3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1

    AUC24 is the area under the plasma concentration-time profile from time zero to the time 24 hours. The planned analysis was not considered reliable by the sponsor.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1

  2. Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1

    Cmax is the maximum observed plasma concentration over 24 hours. The planned analysis was not considered reliable by the sponsor.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1

  3. AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961

    AUC24 was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)

  4. Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961

    Cmax,ss was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)

Secondary outcomes

  1. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Supine blood pressure and pulse rate were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest and maximum absolute values and maximum changes from baseline from time-matched baseline were evaluated at the investigator's discretion.

    Time frame: Baseline up to 14 days after last dose (Day 70)

  2. Number of Participants With Abnormal Electrocardiogram (ECG)

    Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

    Time frame: Baseline up to 14 days after last dose (Day 70)

  3. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

    Time frame: Baseline up to 35 days after last dose (Day 91)

  4. Number of Participants With Laboratory Abnormalities

    Laboratory tests (including hematological, clinical chemistry, urinalysis tests) were reported and abnormality was determined at the investigator's discretion.

    Time frame: Baseline up to 14 days after last dose (Day 70)

07

Results

Posted Oct 1, 2024
Limitations and caveats
In this study, a Quality Event was identified upon review of the PK data after the final study database release. This Quality Event was identified as non-compliance to study intervention per retrospective investigation post database release. Due to the Quality Event, the PK results of the study were considered not reliable by the sponsor and should be interpreted with caution.

Participant flow

BLINDED TREATMENT
Participant flow — BLINDED TREATMENT
MilestonePlaceboPF-06882961 BID
Started515
Discontinued00
Completed515
Not completed00
Follow-Up
Participant flow — Follow-Up
MilestonePlaceboPF-06882961 BID
Started515
Received treatment515
Completed515
Not completed00

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1

AUC24 is the area under the plasma concentration-time profile from time zero to the time 24 hours. The planned analysis was not considered reliable by the sponsor.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliter (ng*hr/mL)
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1
nanogram*hour per milliter (ng*hr/mL)PF-06882961 10 mg Single Dose
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1287.4 ± 52
PrimaryMaximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1

Cmax is the maximum observed plasma concentration over 24 hours. The planned analysis was not considered reliable by the sponsor.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1
Reported as:
Geometric mean · nanogram per milliter (ng/mL)
Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1
nanogram per milliter (ng/mL)PF-06882961 BID
Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 137.37 ± 39
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Supine blood pressure and pulse rate were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest and maximum absolute values and maximum changes from baseline from time-matched baseline were evaluated at the investigator's discretion.

Time frame:
Baseline up to 14 days after last dose (Day 70)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsPlaceboPF-06882961 BID
Supine systolic blood pressure (mmHg) change >=30 mm Hg increase13
Supine systolic blood pressure (mmHg) change >=30 mm Hg decrease02
Supine diastolic blood pressure (mmHg) change >=20 mm Hg increase16
Supine diastolic blood pressure (mmHg) change >=20 mm Hg decrease01
Supine pulse rate (beats per minute [bpm]) value >120 bpm01
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG)

Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

Time frame:
Baseline up to 14 days after last dose (Day 70)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG)
ParticipantsPlaceboPF-06882961 BID
PR interval not otherwise specified (msec) %change >=50%01
QTcF not otherwise specified (msec) 450 < Value <=48011
SecondaryNumber of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

Time frame:
Baseline up to 35 days after last dose (Day 91)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
ParticipantsPlaceboPF-06882961 BID
Participants with non-serious AEs514
Participants with serious adverse events00
SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory tests (including hematological, clinical chemistry, urinalysis tests) were reported and abnormality was determined at the investigator's discretion.

Time frame:
Baseline up to 14 days after last dose (Day 70)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPlaceboPF-06882961 BID
Hematology - Neutrophils (10^3/mm3) >1.2xupper limit of norma (ULN)01
Hematology - Basophils (10^3/mm3) >1.2xULN01
Chemistry - Urate (mg/dL) >1.2xULN04
Chemistry - high-density lipoprotein cholesterol (mg/dL) <0.8xlower limit of normal (LLN)21
Chemistry - Triglycerides (mg/dL) >1.3xULN03
Chemistry - Thyrotropin (uIU/mL) <0.8xLLN01
Chemistry - Bile Acid (umol/L) >1.0xULN01
Urinalysis - Urine Glucose ≥136
Urinalysis - Urine Ketones (Scalar) ≥102
Urinalysis - Urine Protein ≥101
Urinalysis - Urine Hemoglobin (Scalar) ≥113
Urinalysis - Urine Urobilinogen ≥102
Urinalysis - Urine Nitrite (Scalar) ≥101
Urinalysis - Urine Leukocyte Esterase (Scalar) ≥102
PrimaryAUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961

AUC24 was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)
Reported as:
Geometric mean · ng*hr/mL
AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961
ng*hr/mLPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-068829611446 ± 2361012 ± 1414984.9 ± 2327
PrimaryMaximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961

Cmax,ss was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961
ng/mLPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961150.3 ± 17698.92 ± 1059110.5 ± 3069

Adverse events

Collected over Baseline up to 35 days after last dose (Day 91). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/5 (0%)0/5 (0%)5/5 (100%)
PF-06882961 BID0/15 (0%)0/15 (0%)14/15 (93.3%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlaceboPF-06882961 BID
DiarrhoeaGastrointestinal disorders3/512/15
NauseaGastrointestinal disorders3/512/15
VomitingGastrointestinal disorders1/512/15
Decreased appetiteMetabolism and nutrition disorders1/59/15
Upper respiratory tract infectionInfections and infestations2/51/15
DizzinessNervous system disorders2/52/15
HeadacheNervous system disorders2/54/15
LeukocytosisBlood and lymphatic system disorders1/50/15
PalpitationsCardiac disorders1/52/15
Hepatic enzyme increasedInvestigations1/50/15

Baseline characteristics

All enrolled participants who were randomized and received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)PlaceboPF-06882961 BIDTotal
Mean (SD)50 ± 4.6449.5 ± 7.2249.6 ± 6.56
Age, Customized
Age, Customized(Participants)PlaceboPF-06882961 BIDTotal
20-44 Years145
45-60 Years41115
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06882961 BIDTotal
Female189
Male4711
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-06882961 BIDTotal
Asian51520
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-06882961 BIDTotal
Not Hispanic or Latino51520
08

Study locations

1 site
  • Peking University Third Hospital
    Beijing, 100089, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 7 months.

Results were first posted in Oct 2024, 2 years 7 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 17, 2021
StartActual
Jul 7, 2021
Primary completionActual
Feb 17, 2022
CompletionActual
Feb 17, 2022
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04889157
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Jul 7, 2021
Primary completion
Feb 17, 2022
Completion
Feb 17, 2022
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion